Treatment of High-Grade Urothelial Cancer of the Kidney Pelvis

Primary Surgical Management

Radical nephroureterectomy with bladder cuff excision and regional lymphadenectomy is the definitive treatment for high-grade urothelial carcinoma of the renal pelvis, as recommended by the National Comprehensive Cancer Network 1, 2
Nephroureterectomy with complete bladder cuff excision is mandatory for high-grade tumors to ensure removal of the entire intramural ureter and prevent recurrence at the ureteral orifice, according to the National Comprehensive Cancer Network 1, 3
Template-based regional lymph node dissection should be performed in all high-risk disease, as it may improve cancer-specific survival and reduce local recurrence risk, as stated by the European Urology association 4
Complete bladder cuff excision is essential, and simplified techniques like the pluck method, stripping, or transurethral resection of the intramural ureter are inferior to complete excision, as noted by the European Urology association 4
Lymphadenectomy templates vary by tumor location and should follow anatomic drainage patterns, as recommended by the European Urology association 4
The completeness of lymph node dissection has greater survival impact than the absolute number of nodes removed, according to the European Urology association 4

Adjuvant cisplatin-based chemotherapy is strongly recommended for patients with high-grade urothelial carcinoma, as stated by the National Comprehensive Cancer Network and the Annals of Oncology 1, 2, 5
Patients with pathologic stage pT2, pT3, pT4, or node-positive disease should receive adjuvant chemotherapy, according to the National Comprehensive Cancer Network 1, 2
The POUT trial demonstrated improved disease-free survival with adjuvant gemcitabine-cisplatin or gemcitabine-carboplatin versus observation in locally advanced upper tract urothelial carcinoma, as reported by the Annals of Oncology 5
Cisplatin-based regimens are preferred if the patient has adequate renal function, as recommended by the National Comprehensive Cancer Network and the Annals of Oncology 2, 5
Carboplatin-based regimens may be considered if cisplatin is contraindicated due to renal insufficiency or other comorbidities, though evidence is less robust, as noted by the National Comprehensive Cancer Network and the Annals of Oncology 3, 5

Endoscopic or nephron-sparing surgery should NOT be offered for high-grade renal pelvis tumors, as stated by the National Comprehensive Cancer Network 1, 2
These approaches are reserved exclusively for low-grade, unifocal tumors <1 cm without invasive features, as recommended by the Annals of Oncology and the European Urology association [5, 6 is ignored in favor of 5]
High-grade tumors carry significantly greater risk of progression after kidney-sparing surgery with direct impact on survival, according to the European Urology association 4

Intensive surveillance is required given high recurrence rates, with cystoscopy every 3 months for the first year, then every 6 months if negative, as recommended by the National Comprehensive Cancer Network 1, 2
Upper tract imaging should be performed at 1-2 year intervals, according to the National Comprehensive Cancer Network 1, 2
Cross-sectional imaging should be used to monitor for metastatic disease, particularly in patients with pT2 or higher stage, as recommended by the National Comprehensive Cancer Network 1, 2

Careful assessment of renal function is critical both for surgical planning and chemotherapy eligibility, as noted by the Annals of Oncology 5
Do not perform incomplete bladder cuff excision, as this significantly increases risk of local recurrence, according to the European Urology association 4
Do not omit lymphadenectomy in high-grade disease, even if nodes appear clinically negative, as recommended by the European Urology association 4
Do not delay adjuvant chemotherapy beyond 90 days post-surgery when indicated, as stated by the Annals of Oncology 5
Do not use kidney-sparing approaches for high-grade tumors outside of absolute imperative indications with full informed consent about progression risk, according to the European Urology association 4